Psychiatry and Neurology, Epilepsy · Grand Rapids, MI
NPI
1679648315
Since 2006
Specialty
Psychiatry and Neurology, Epilepsy
Code 2084E0001X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
275 Michigan St NE
Grand Rapids, MI, 49503
Phone (616) 267-7900
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
476 services
Medicare patients, 2024
204
Average age 64
Drug cost, 2024
$4.2M
3,303 prescriptions
Company payments, 2025
$362K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David E Burdette was code 95720 (neurologic), 139 times for 71 patients. In total David E Burdette billed 476 services in 28 codes, and Medicare paid $51K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-12-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95720 Neurologic | Facility | 139 | 71 | $162.00 | $23K |
| 95718 Neurologic | Facility | 95 | 88 | $95.77 | $9,098 |
| 99214 Office E&M - Established | Office | 37 | 31 | $81.85 | $3,028 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 32 | 24 | $11.97 | $383 |
| 99215 Office E&M - Established | Office | 31 | 24 | $116.08 | $3,599 |
By year: 2022 $65K for 591 services; 2023 $58K for 503 services; 2024 $51K for 476 services.
Medicare prescription drug claims, 2024
In 2024, the drug David E Burdette prescribed most often to Medicare patients was Xcopri (Cenobamate), with 535 prescriptions and refills. In total David E Burdette wrote 3,303 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xcopri Cenobamate | 535 | 586 | 55 | $945K |
| Lacosamide Generic | 488 | 647 | 74 | $75K |
| Clobazam Generic | 286 | 380 | 44 | $26K |
| Briviact Brivaracetam | 263 | 281 | 36 | $531K |
| Lamotrigine Generic | 226 | 427 | 38 | $6,332 |
| Levetiracetam Generic | 168 | 334 | 36 | $9,108 |
| Epidiolex Cannabidiol (Cbd) | 143 | 155 | 16 | $883K |
| Zonisamide Generic | 123 | 211 | 23 | $4,034 |
| Nayzilam Midazolam | 96 | 96 | 28 | $114K |
| Divalproex Sodium Generic | 94 | 126 | 11 | $7,665 |
| Topiramate Generic | 74 | 110 | 11 | $1,238 |
| Divalproex Sodium Er Divalproex Sodium | 64 | 115 | 13 | $3,170 |
| Fycompa Perampanel | 55 | 62 | Under 11 | $87K |
| Felbamate Generic | 46 | 64 | Under 11 | $14K |
| Lamotrigine Er Lamotrigine | 42 | 50 | Under 11 | $5,578 |
Brand drugs: 1,267 claims; generic drugs: 2,036 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David E Burdette $362K ($273K in general payments such as food, travel and fees and $89K for research) from 12 companies. The largest payer was Neuropace, Inc. with $143K.
| Company | Payments | Amount |
|---|---|---|
| Neuropace, Inc. NPCE | 225 | $143K |
| UCB, Inc. UCB.BR | 119 | $107K |
| Jazz Pharmaceuticals Inc. JAZZ | 58 | $75K |
| SK Life Science, Inc. | 27 | $25K |
| Ucb Sa UCB.BR | 3 | $12K |
| Orthofix Medical, Inc. OFIX | 1 | $134 |
| Neurelis, Inc. | 1 | $37.49 |
| Upsher-Smith Laboratories LLC | 1 | $29 |
| Catalyst Pharmaceuticals, Inc. CPRX | 1 | $28.94 |
| Xeris Pharmaceuticals, Inc. | 1 | $27.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.